Mark M. Yore

3.8k total citations · 2 hit papers
21 papers, 3.1k citations indexed

About

Mark M. Yore is a scholar working on Molecular Biology, Biochemistry and Oncology. According to data from OpenAlex, Mark M. Yore has authored 21 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 4 papers in Biochemistry and 3 papers in Oncology. Recurrent topics in Mark M. Yore's work include Genomics, phytochemicals, and oxidative stress (9 papers), Natural product bioactivities and synthesis (6 papers) and Retinoids in leukemia and cellular processes (6 papers). Mark M. Yore is often cited by papers focused on Genomics, phytochemicals, and oxidative stress (9 papers), Natural product bioactivities and synthesis (6 papers) and Retinoids in leukemia and cellular processes (6 papers). Mark M. Yore collaborates with scholars based in United States, United Kingdom and Sweden. Mark M. Yore's co-authors include Michael B. Sporn, Karen T. Liby, Gordon W. Gribble, Barbara B. Kahn, Pedro M. Moraes‐Vieira, Ismail Syed, Tadashi Honda, Pratik Aryal, Ann Hammarstedt and Ulf Smith and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Mark M. Yore

21 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discovery of a Class of Endogenous Mammalian Lipids with Anti-Diabetic and Anti-inflammatory Effects

2014 648 citations Mark M. Yore, Ismail Syed et al. Cell profile →
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer

2007 529 citations Karen T. Liby, Mark M. Yore et al. Nature reviews. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark M. Yore United States	19	2.2k	531	422	275	257	21	3.1k
Josefa Girona Spain	31	1.1k 0.5×	383 0.7×	500 1.2×	208 0.8×	348 1.4×	108	2.5k
József Mandl Hungary	33	1.3k 0.6×	346 0.7×	384 0.9×	102 0.4×	183 0.7×	108	3.0k
Taro E. Akiyama United States	30	2.4k 1.1×	734 1.4×	574 1.4×	292 1.1×	416 1.6×	70	3.9k
Mi-Kyoung Kwak United States	20	3.1k 1.4×	252 0.5×	241 0.6×	310 1.1×	280 1.1×	22	3.7k
Keon Wook Kang South Korea	30	1.7k 0.8×	209 0.4×	292 0.7×	315 1.1×	295 1.1×	87	2.7k
Heqing Huang China	35	1.7k 0.8×	367 0.7×	451 1.1×	512 1.9×	250 1.0×	92	3.5k
Jonathan Maher United States	35	2.3k 1.0×	205 0.4×	479 1.1×	240 0.9×	300 1.2×	53	4.2k
Lisa M. Leesnitzer United States	22	1.7k 0.7×	436 0.8×	161 0.4×	320 1.2×	399 1.6×	30	2.4k
Nicholas K.H. Khoo United States	28	985 0.4×	718 1.4×	207 0.5×	263 1.0×	124 0.5×	38	2.2k
Elena Chiarpotto Italy	32	1.5k 0.7×	635 1.2×	372 0.9×	460 1.7×	318 1.2×	75	3.5k

Countries citing papers authored by Mark M. Yore

Since Specialization

Citations

This map shows the geographic impact of Mark M. Yore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark M. Yore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark M. Yore more than expected).

Fields of papers citing papers by Mark M. Yore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark M. Yore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark M. Yore. The network helps show where Mark M. Yore may publish in the future.

Co-authorship network of co-authors of Mark M. Yore

This figure shows the co-authorship network connecting the top 25 collaborators of Mark M. Yore. A scholar is included among the top collaborators of Mark M. Yore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark M. Yore. Mark M. Yore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moraes‐Vieira, Pedro M., Mark M. Yore, Alexandra Sontheimer-Phelps, et al.. (2020). Retinol binding protein 4 primes the NLRP3 inflammasome by signaling through Toll-like receptors 2 and 4. Proceedings of the National Academy of Sciences. 117(49). 31309–31318. 66 indexed citations

Syed, Ismail, Jennifer Lee, Pedro M. Moraes‐Vieira, et al.. (2018). Palmitic Acid Hydroxystearic Acids Activate GPR40, Which Is Involved in Their Beneficial Effects on Glucose Homeostasis. Cell Metabolism. 27(2). 419–427.e4. 150 indexed citations

Yore, Mark M., Ismail Syed, Pedro M. Moraes‐Vieira, et al.. (2014). Discovery of a Class of Endogenous Mammalian Lipids with Anti-Diabetic and Anti-inflammatory Effects. Cell. 159(2). 318–332. 648 indexed citations breakdown →

Moraes‐Vieira, Pedro M., et al.. (2014). RBP4 Activates Antigen-Presenting Cells, Leading to Adipose Tissue Inflammation and Systemic Insulin Resistance. Cell Metabolism. 19(3). 512–526. 222 indexed citations

Norseen, Julie, Tetsuya Hosooka, Ann Hammarstedt, et al.. (2012). Retinol-Binding Protein 4 Inhibits Insulin Signaling in Adipocytes by Inducing Proinflammatory Cytokines in Macrophages through a c-Jun N-Terminal Kinase- and Toll-Like Receptor 4-Dependent and Retinol-Independent Mechanism. Molecular and Cellular Biology. 32(10). 2010–2019. 211 indexed citations

Yore, Mark M., Arminja N. Kettenbach, Michael B. Sporn, Scott A. Gerber, & Karen T. Liby. (2011). Proteomic Analysis Shows Synthetic Oleanane Triterpenoid Binds to mTOR. PLoS ONE. 6(7). e22862–e22862. 83 indexed citations

Liby, Karen T., Renee Risingsong, Darlene B. Royce, et al.. (2009). Triterpenoids CDDO-Methyl Ester or CDDO-Ethyl Amide and Rexinoids LG100268 or NRX194204 for Prevention and Treatment of Lung Cancer in Mice. Cancer Prevention Research. 2(12). 1050–1058. 50 indexed citations

Liby, Karen T., Renee Risingsong, Darlene B. Royce, et al.. (2008). Prevention and Treatment of Experimental Estrogen Receptor–Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268. Clinical Cancer Research. 14(14). 4556–4563. 66 indexed citations

Liby, Karen T., Mark M. Yore, Bill D. Roebuck, et al.. (2008). A Novel Acetylenic Tricyclic bis-(Cyano Enone) Potently Induces Phase 2 Cytoprotective Pathways and Blocks Liver Carcinogenesis Induced by Aflatoxin. Cancer Research. 68(16). 6727–6733. 42 indexed citations

10.

Liby, Karen T., Candice C. Black, Darlene B. Royce, et al.. (2008). The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Molecular Cancer Therapeutics. 7(5). 1251–1257. 31 indexed citations

11.

Liby, Karen T., Mark M. Yore, & Michael B. Sporn. (2007). Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nature reviews. Cancer. 7(5). 357–369. 529 indexed citations breakdown →

12.

Liby, Karen T., Darlene B. Royce, Charlotte R. Williams, et al.. (2007). The Synthetic Triterpenoids CDDO-Methyl Ester and CDDO-Ethyl Amide Prevent Lung Cancer Induced by Vinyl Carbamate in A/J Mice. Cancer Research. 67(6). 2414–2419. 124 indexed citations

13.

Sporn, Michael B., Karen T. Liby, Mark M. Yore, et al.. (2007). Platforms and networks in triterpenoid pharmacology. Drug Development Research. 68(4). 174–182. 33 indexed citations

14.

Yore, Mark M., et al.. (2006). The synthetic triterpenoid, CDDO-Imidazolide blocks nuclear factor-κB activation through direct inhibition of IκB kinase-beta.. Cancer Epidemiology and Prevention Biomarkers. 15. 4 indexed citations

15.

Yore, Mark M., Karen T. Liby, Tadashi Honda, Gordon W. Gribble, & Michael B. Sporn. (2006). The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-κB activation through direct inhibition of IκB kinase β. Molecular Cancer Therapeutics. 5(12). 3232–3239. 101 indexed citations

16.

Ogden, Stacey K., David Casso, Manuel Ascano, et al.. (2006). Smoothened Regulates Activator and Repressor Functions of Hedgehog Signaling via Two Distinct Mechanisms. Journal of Biological Chemistry. 281(11). 7237–7243. 16 indexed citations

17.

Yates, Melinda S., Mi-Kyoung Kwak, Patricia A. Egner, et al.. (2006). Potent Protection against Aflatoxin-Induced Tumorigenesis through Induction of Nrf2-Regulated Pathways by the Triterpenoid 1-[2-Cyano-3-,12-Dioxooleana-1,9(11)-Dien-28-Oyl]Imidazole. Cancer Research. 66(4). 2488–2494. 165 indexed citations

18.

Yore, Mark M., et al.. (2005). Limiting Effects of RIP140 in Estrogen Signaling. Journal of Biological Chemistry. 280(9). 7829–7835. 25 indexed citations

19.

Liby, Karen T., Thomas Hock, Mark M. Yore, et al.. (2005). The Synthetic Triterpenoids, CDDO and CDDO-Imidazolide, Are Potent Inducers of Heme Oxygenase-1 and Nrf2/ARE Signaling. Cancer Research. 65(11). 4789–4798. 239 indexed citations

20.

Yore, Mark M., et al.. (2003). Negative Feedback at the Level of Nuclear Receptor Coregulation. Journal of Biological Chemistry. 278(45). 43889–43892. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact